Your current position:HOME > Products & Services > Tumor Gene Detection > Pancreatic Cancer
Products & Services
Summary of Pancreatic Cancer
Pancreatic cancer is the most common and malignant tumor of digestive system. Globally the survival rate of advanced pancreatic cancer is very low, the survival rate in 5 years is less than 4%.when people's lifestyle become westernized, the morbidity of pancreatic cancer is rising obviously. In the developed areas such as Shanghai in our country, the new cases of pancreatic cancer are increasing fast. According to latest statistic data, there were about 90,000 new cases of pancreatic cancer in our country in 2015. Smoking, drinking, obesity and chronic pancreatitis are the precipitating factors, diabetes is also one of the dangerous factors.

Scientific studies have verified that a cancer is caused by the genetic mutation of human body, genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore, it is regarded as a first choice for advanced cancer patients in multiple cancer types. Presently, the Erlotinib, Everolimus, Sunitinib and so on have been approved by FDA/CFDA. But, the gene variations carried by different patients are different, which makes patients with different sensitivity, toxic and adverse effects for same antineoplastic drugs.

 The precision diagnosis is a prerequisite for accurate medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by pancreatic cancer patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.

  The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.
Pancreas core™

Individualized medication gene detection of pancreatic cancer

Burning Rock Pancreas core™, aiming at the pancreatic cancer patients, by adopting the advanced second generation sequencing technology, can fully detect the drug-inhibited target genes relating to pancreatic cancer and provide prefect references for selection of individualized treatment schemes of pancreatic cancer patients clinically. 。

Genes covered in Pancreas core™


Targeted drugs covered in Pancreas core™


More comprehensive individualized medication selection

Pancreas coreTM can fully detect the drug-inhibited target genes suggested in pancreatic cancer NCCN guideline, drug-inhibited targets being researched in clinical trial of phaseⅡ/Ⅲpancreatic cancer and approved drug-inhibited targets of all cancers, to provide most comprehensive individualized medication gene detecting for pancreatic cancer patients.

More accurate gene mutation detection related to pancreatic cancer:

The gene detection Panel based on the second generation sequencing technology optimized by Burning Rock Dx, can detect 4 types of variation types at one time (mutation, insertion and deletion, fusion, amplification, etc.), at the same time, applies deep sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. On the one hand, the parallel detecting with the polygenic high sensitivity  improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; On the other hand, the complete coverage of exons can detect the hot spots and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation,  having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.

More professional detection report interpretation:

Buring Rock Dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. The improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.

Applicable Populations


Sample Requirements

Operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.

Service Cycle

After sample inspection, detailed detection report will be issued in 10 natural days.

Service Procedure

Cases Sharing